Lataa...
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
BACKGROUND: Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. Plk1 is upregulated in many tumor types including colorectal cancer (CRC) and portends a poor prognosis. TAK-960 is an ATP-competitive Plk1 inhibitor that has demonst...
Tallennettuna:
| Julkaisussa: | BMC Cancer |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5800287/ https://ncbi.nlm.nih.gov/pubmed/29402316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4036-z |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|